title: Evidence-based hypertension treatment in patients with diabetes.
abstract: Both impaired glucose tolerance and diabetes are associated with substantially increased prevalence of hypertension, cardiovascular and renal disease. The goal for hypertension treatment in diabetic patients is in evolution, because of recent clinical trials. For example, the results of the recent Action to Control Cardiovascular Risk in Diabetes-BP Arm (ACCORD BP) trial failed to show an additional benefit on cardiovascular event reduction at a mean systolic BP of 119 mm Hg. A post hoc analysis of 6,400 patients with type 2 diabetes from the International Verapamil-Trandolapril Study (INVEST) also failed to show additional cardiovascular risk reduction among patients who achieved a BP <130/80 mm Hg. While the evidence fails to support a lower BP goal to reduce coronary events, there was a risk reduction in stroke events both in ACCORD and the Appropriate Blood Pressure Control in NIDDM (ABCD) trial. A number of other clinical trials also demonstrate that when systolic pressures fall to less than 130 mm Hg, a reduction in stroke but not coronary disease events occurs. Thus, the precise BP goal for diabetic patients remains unresolved. We would posit that a BP goal of 135/85 mm Hg may be a reasonable compromise when viewing the impact of BP reduction on composite stroke and coronary artery disease in extant trials.
authors.affiliation: From the Division of Endocrinology, Diabetes & Metabolism, Department of Internal Medicine, University of Missouri ; 1 the Department of Medical Physiology and Pharmacology ; 2 and the Harry S. Truman VA Medical Center, Columbia, MO 3.
authors.forename: Mariana
authors.initials: M
authors.lastname: Garcia-Touza
authors.affiliation: From the Division of Endocrinology, Diabetes & Metabolism, Department of Internal Medicine, University of Missouri ; 1 the Department of Medical Physiology and Pharmacology ; 2 and the Harry S. Truman VA Medical Center, Columbia, MO 3.
authors.forename: James R
authors.initials: JR
authors.lastname: Sowers
mesh_terms: D000419:Albuminuria / Q000517:prevention & control; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000517:prevention & control; D004730:Endothelium, Vascular / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007333:Insulin Resistance / Q000502:physiology; D007676:Kidney Failure, Chronic / Q000517:prevention & control; D019808:Losartan / Q000627:therapeutic use; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic
chemical_list: D000959:Antihypertensive Agents; D019808:Losartan